PDF(Pubmed)
Abstract：
With the widespread application of immune checkpoint inhibitors, a series of adverse events (AEs) related to treatment resulting from alterations in the immune system have emerged that warrant attention. The present study report the case of a patient with reactive cutaneous capillary endothelial proliferations (RCCEPs) on the eye lid, following treatment with the programmed cell death protein 1 inhibitor camrelizumab (SHR-1210) for stage IIa2 well- to moderately differentiated squamous cell carcinoma of the cervix. Although RCCEPs have been revealed to be the most common AEs of SHR-1210, they are usually distributed on the head, neck, trunk and extremities. The current study presents a rare case of ocular RCCEPs induced by SHR-1210. Prompt diagnosis and treatment of immune-related AEs is crucial for the optimal management of patients. Although RCCEPs are usually slight-risk toxicities that pose no threat to the continuity of treatment, lesions with unusual distributions that cause disturbances in normal life require proper treatment, such as surgical excision.
摘要：
随着免疫检查点抑制剂的广泛应用,免疫系统改变导致的一系列与治疗相关的不良事件(AE)已经出现,值得关注.本研究报告了一例眼睑上有反应性皮肤毛细血管内皮增生（RCCEPs）的患者，在使用程序性细胞死亡蛋白1抑制剂camrelizumab（SHR-1210）治疗IIa2期至中分化宫颈鳞状细胞癌之后。尽管已发现RCCEP是SHR-1210最常见的AE，但它们通常分布在头部，脖子,躯干和四肢。当前的研究提出了由SHR-1210诱导的眼部RCCEP的罕见病例。及时诊断和治疗免疫相关的AE对于患者的最佳管理至关重要。尽管RCCEPs通常是轻微风险的毒性，对治疗的连续性没有威胁，引起正常生活紊乱的异常分布的病变需要适当的治疗，如手术切除。
